Stivarga

RSS

regorafenib

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Stivarga. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Stivarga.

For practical information about using Stivarga, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 08/03/2023

Authorisation details

Product details
Name
Stivarga
Agency product number
EMEA/H/C/002573
Active substance
regorafenib
International non-proprietary name (INN) or common name
regorafenib
Therapeutic area (MeSH)
Colorectal Neoplasms
Anatomical therapeutic chemical (ATC) code
L01EX05
Publication details
Marketing-authorisation holder
Bayer Pharma AG
Revision
20
Date of issue of marketing authorisation valid throughout the European Union
26/08/2013
Contact address
13342 Berlin
Germany

Product information

07/03/2023 Stivarga - EMEA/H/C/002573 - IAIN/0040

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Antineoplastic agents

  • Protein kinase inhibitors

Therapeutic indication

Stivarga is indicated as monotherapy for the treatment of adult patients with:

  • metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies - these include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy;
  • unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib;
  • hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
Average
2 ratings
1 rating
2 ratings